PPARδ comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Updated 2025-11-08. Numbers and descriptions here follow the published literature rather than marketing material.
Regulatory treatment varies, but cardarine is not approved as a medicine. Sports authorities list GW501516 as a prohibited substance, and it is banned at all times under the World Anti-Doping Agency code. Many countries restrict sales for human consumption, while online vendors market it as a research chemical. Such products may lack purity data, and their actual contents can differ from the label. Purchasing or possessing cardarine may carry legal consequences depending on jurisdiction. The compound is not a dietary supplement ingredient in regulated markets.
Clinical development stopped after rodent studies showed tumors at multiple sites. Whether those findings predict human cancer risk remains an open question, but they led sponsors to discontinue programs. Human safety data are limited to small, short-term studies that were not designed to assess cancer risk. Reported effects in those studies included changes in blood lipids, but the evidence is insufficient for medical use. Long-term consequences of nonmedical use are not well characterized. Questions about dose, duration, and individual susceptibility remain unresolved.
Laboratory handling focuses on identity, purity, and stability. Reference standards are typically stored cold and dry, protected from light, because solutions can degrade over time. Analytical checks may use high-performance liquid chromatography with ultraviolet detection or mass spectrometry. Impurities and related substances can be separated chromatographically and compared with a known standard. Because cardarine is not an approved drug, compendial monographs are absent, and laboratories often rely on in-house methods. Reported purity varies among unregulated products and should not be assumed from a label.
GW501516 binds and activates PPARδ, a nuclear receptor that influences transcription of genes involved in fatty acid oxidation and energy use. Activation shifts some metabolic pathways in preclinical models, which is why the compound has been studied for lipid disorders and exercise-related endpoints. The exact downstream effects in humans are incompletely mapped. PPARδ is expressed in many tissues, including skeletal muscle, liver, and adipose tissue, so broad activation may have varied consequences. Researchers continue to examine how selective or partial activation might alter the balance between benefits and risks.
| Property | Value | Notes |
|---|---|---|
| Common synonyms | GW501516; GW-1516; endurobol | GW501516 is the research code |
| Drug class | PPARδ agonist | Not a selective androgen receptor modulator |
| Molecular formula | C21H18F3NO3S2 | Established chemical formula |
| Molar mass | 453.5 g/mol | Calculated from the formula |
| Regulatory status | Prohibited in sport; not approved as medicine | Status varies by country |
Literature on cardarine often separates receptor pharmacology from toxicology. Mechanistic papers describe PPARδ activation and gene expression changes, while safety assessments focus on carcinogenicity and species differences. Questions remain about whether rodent tumors arise through PPARδ-dependent or off-target mechanisms. Another open area is how human metabolism and exposure compare with those in animal studies. Analytical methods such as liquid chromatography–mass spectrometry are used to confirm identity in biological and product samples.
GW501516 acts as an agonist at the peroxisome proliferator-activated receptor delta, a nuclear receptor that regulates gene expression. Activation shifts transcription toward genes involved in fatty acid uptake, oxidation, and energy expenditure. The compound does not bind the androgen receptor and therefore differs from anabolic steroids and SARMs. In rodent models, this metabolic shift has been linked to increased running endurance and reduced fat accumulation. The exact downstream pathways in humans remain incompletely characterized.
Regulatory bodies treat GW501516 as a prohibited substance in competitive sport. The World Anti-Doping Agency added it to the prohibited list, and it falls under classes covering metabolic modulators and hormone-related agents. It is not approved by drug regulators for human use, and it is not a lawful dietary supplement. Products sold under the cardarine name may contain unlisted ingredients or different compounds. Because no approved product exists, quality and identity are not guaranteed by pharmaceutical manufacturing standards.
Cardarine is a common name for the investigational chemical GW501516, also written GW-1516. It was developed as a peroxisome proliferator-activated receptor delta agonist for metabolic conditions such as dyslipidemia. Early research focused on lipid handling and energy use in skeletal muscle and other tissues. The compound was never approved as a medicine. In public discussion, it is often grouped with performance-enhancing substances, although its receptor target differs from that of anabolic steroids or selective androgen receptor modulators. Regulatory and health authorities have issued warnings about its use.
GW501516 acts on PPARδ, a nuclear receptor that helps regulate fatty acid oxidation and energy homeostasis. In animal studies, activation of this receptor was associated with increased endurance and changes in lipid metabolism. Human trials examined effects on blood lipids and other metabolic markers, but the compound did not advance to approval. Rodent studies later reported tumors in multiple tissues at doses used in those experiments. Whether those findings translate to human risk remains uncertain, and the clinical relevance of the animal data is still debated.
Quality assessment for cardarine samples usually combines identity, purity, and impurity testing. Nuclear magnetic resonance spectroscopy and mass spectrometry can confirm molecular structure, while high-performance liquid chromatography estimates purity. Certificates of analysis from testing laboratories may list these results, but they do not establish safety or legality. In the absence of approved manufacturing, products sold online may contain the wrong compound, variable amounts, or unlisted contaminants. Independent verification is therefore central to analytical work and to interpreting any reported biological activity.
Laboratory detection of GW501516 commonly uses liquid chromatography coupled with tandem mass spectrometry. The method can identify the parent compound or its metabolites in urine and blood after sample cleanup. Protein precipitation, solid-phase extraction, or enzymatic hydrolysis may precede analysis, depending on the matrix. Reference standards are required for accurate quantification and confirmation. Because the compound is not approved, testing often occurs in anti-doping, forensic, or research settings rather than routine clinical care. Results are reported with limits of detection and quantification.
Stability of GW501516 depends on form, temperature, light exposure, and moisture. Solid reference material is typically stored frozen or refrigerated in a desiccator and protected from light. Solutions in organic solvents such as dimethyl sulfoxide are often kept frozen in aliquots to reduce freeze-thaw cycling. Aqueous solubility is low, so aqueous stock solutions can be difficult to prepare without cosolvents. Degradation may appear as changes in chromatographic purity or mass spectral signal. Stability studies are needed to establish shelf life for any specific preparation.
Rates of metformin-associated lactic acidosis are about nine per 100,000 persons/year, which is similar to the background rate of lactic acidosis in the general population. Systematic reviews from 2003 and 2022 concluded no data exists to definitively link metformin to lactic acidosis. Metformin-associated lactate production may also take place in the large intestine, which could potentially contribute to lactic acidosis in those with risk factors. The clinical significance of this is unknown, though, and the risk of metformin-associated lactic acidosis is most commonly attributed to decreased hepatic uptake rather than increased intestinal production.
=== Biofuel production === One the most widely known biobased chemicals produced through fermentation, the process of fermenting sugars from plants into ethanol and CO2 uses Saccharomyces cerevisiae. Biobased ethanol is used as a popular renewable transportation fuel and also holds value in the chemical industry as the precursor for ethylene, which can be converted into polyethylene. Commercial bioethanol production via fermentation is dominant in Brazil and the USA and employs sugarcane and starch from corn as feedstocks. The process involves starch enzymatic hydrolysis to glucose, followed by fermentation and distillation. There were around 200 ethanol plants operating in the U.S. as of 2021, with capacities of production varying from 6 kilotonnes to over one million tonnes annually.
=== Capillary rise of liquid between two glass plates === The product of layer thickness (d) and elevation height (h) is constant (d·h = constant), the two quantities are inversely proportional. The surface of the liquid between the planes is hyperbola.
=== Pregnancy === It is possible that relaxin in the placenta could be a contributing factor to inducing labour in humans and therefore serum relaxin levels during pregnancy have been linked to premature birth.
During Nixon's term, some 70% of federal anti-drug money was spent on demand-side public health measures, and 30% on supply-side interdiction and punishment, a funding ratio not repeated under subsequent administrations. The war on drugs under the next two presidents, Gerald Ford (1974–77) and Jimmy Carter (1977–81), was essentially a continuation of their predecessors' policies. Carter's campaign platform included decriminalization of cannabis and an end to federal penalties for possession of up to one ounce. In a 1977 "Drug Abuse Message to the Congress", Carter stated, "Penalties against possession of a drug should not be more damaging to an individual than the use of the drug itself." None of his advocacy was translated into law.
Sources: en.wikipedia.org
== Synopsis == Reagents are "substances or compounds that are added to a system in order to bring about a chemical reaction or are added to see if a reaction occurs." Some reagents are just a single element. However, most processes require reagents made of chemical compounds. Some of the most common ones used widely for specific reactive functions are listed below, but is by no means exhaustive.
During withdrawal of bromazepam or diazepam a fall in tryptophan, serotonin levels occurs as part of the benzodiazepine withdrawal syndrome. Changes in the levels of these chemicals in the brain can cause headaches, anxiety, tension, depression, insomnia, restlessness, confusion, irritability, sweating, dysphoria, dizziness, derealization, depersonalization, numbness/tingling of extremities, hypersensitivity to light, sound, and smell, perceptual distortions, nausea, vomiting, diarrhea, appetite loss, hallucinations, delirium, seizures, tremor, stomach cramps, myalgia, agitation, palpitations, tachycardia, panic attacks, short-term memory loss, and hyperthermia.
As mentioned above, prostacyclin (PGI2) is released by healthy endothelial cells and performs its function through a paracrine signaling cascade that involves G protein-coupled receptors on nearby platelets and endothelial cells. The platelet Gs protein-coupled receptor (prostacyclin receptor) is activated when it binds to PGI2. This activation, in turn, signals adenylyl cyclase to produce cAMP. cAMP goes on to inhibit any undue platelet activation (in order to promote circulation) and also counteracts any increase in cytosolic calcium levels that would result from thromboxane A2 (TXA2) binding (leading to platelet activation and subsequent coagulation). PGI2 also binds to endothelial prostacyclin receptors, and in the same manner, raises cAMP levels in the cytosol. This cAMP then goes on to activate protein kinase A (PKA). PKA then continues the cascade by promoting the phosphorylation of the myosin light chain kinase, which inhibits it and leads to smooth muscle relaxation and vasodilation. It can be noted that PGI2 and TXA2 work as physiological antagonists.
In biochemistry, fatty acid synthesis is the process by which fatty acids, the fundamental building blocks of fats, are derived from metabolic intermediates through the coordinated actions of enzymes. Fatty acids (FAs), comprise a large group of chemically heterogeneous compounds. Each fatty acid is composed of a carboxylic acid attached to an aliphatic hydrocarbon chain, of which is either saturated or unsaturated. FAs prove crucial within the cell, as these molecules serve as the indispensable building blocks of cell membranes. FAs also provide dense, long-term energy sources for the cell, and the biosynthetic production of FAs is essential for maintaining cellular homeostasis. Fatty acid biosynthetic pathways are highly evolutionarily conserved across species, though different enzymes and genetic organizations have evolved to reach similarities about the general pathway. In both animals and fungi, all fatty acid synthetic pathways utilize one multifunctional protein complex, type-I fatty acid synthase (FAS), which is divided into the type-Ia FAS (in fungi) and the type-Ib FAS (in animals). In most prokaryotes and in the plastids of plants, fatty acid synthesis occurs via type-II fatty acid synthase (FAS). Fatty acid synthesis occurs in the cytosol, where there is a high NADPH/NADP+ ratio available to drive the reactions forward.
Table 2. Protein interactions found using BioGrid. All interactions were physical interactions and had very confident significant scores. A STRING protein association search yielded no confident results, or ones that seem significant based on previous findings.
Sources: en.wikipedia.org
Mark McVeigh (born 26 January 1981) is a former professional Australian rules footballer who played for and is currently the senior coach of the Essendon Football Club in the Australian Football League (AFL). He served as the caretaker senior coach of the Greater Western Sydney Giants following the resignation of Leon Cameron in 2022. He has been the senior coach of the Essendon Football Club since August 2026.
hit identification using virtual screening (structure- or ligand-based design) hit-to-lead optimization of affinity and selectivity (structure-based design, QSAR, etc.) lead optimization of other pharmaceutical properties while maintaining affinity
== Pathogenicity == Rhizopus oryzae is one of the most common causes of a disease known as mucormycosis, characterized by growing hyphae within and surrounding blood vessels. The causal agents of mucormycosis may also produce toxins like agroclavine which is toxic to humans, sheep and cattle. This infection usually occurs in immunocompromised individuals but is rare. Common risk factors associated with primary cutaneous mucormycosis is ketoacidosis, neutropenia, acute lymphobloastic leukemia, lymphomas, systemic steroids, chemotherapy, and dialysis. Treatment includes amphotericin B, posaconazole, itraconazole, and fluconazole. The majority of the cases of infection are rhinocerebral infections. At the same time, it has been found in literature that R. oryzae can produce antibiotic activity on some bacteria. The pathogenicity towards plants is attributed to the presence of large number of carbohydrate digesting enzymes.
== Fossil record == Fossil leaves and fruits of †Artocarpus dicksoni have been found in Cretaceous formations of West Greenland. Fossil leaves of †Artocarpus ordinarius have been found in Cretaceous stratum at the south bank of the Yukon River just above Rampart, Alaska. Fossils of †Artocarpus californica have been described from Eocene and Miocene strata of the Pacific coast of California and Oregon. Eight fossil species of Artocarpus (†A. capellinii, †A. isseli, †A. macrophylla, †A. massalongoi, †A. multinervis, †A. ovalifolia, †A. sismondai and †A. taramellii), from the lower Oligocene, have been described from a fossil leaves collected from 1857 to 1889 in Santa Giustina and Sassello in Central Liguria, Italy.
==== Remdesivir/baricitinib ==== In May 2020, the National Institute of Allergy and Infectious Diseases (NIAID) started the Adaptive COVID‑19 Treatment Trial 2 (ACTT-2) to evaluate the safety and efficacy of a treatment regimen consisting of remdesivir plus baricitinib for treating hospitalized adults who have a laboratory-confirmed SARS-CoV-2 infection with evidence of lung involvement, including a need for supplemental oxygen, abnormal chest X-rays, or illness requiring mechanical ventilation. In November 2020, the US Food and Drug Administration (FDA) issued an emergency use authorization (EUA) for the drug baricitinib, in combination with remdesivir, for the treatment of suspected or laboratory-confirmed COVID‑19 in hospitalized people two years of age or older requiring supplemental oxygen, invasive mechanical ventilation, or extracorporeal membrane oxygenation (ECMO). The data supporting the EUA for baricitinib combined with remdesivir are based on a randomized, double-blind, placebo-controlled clinical trial (ACTT-2), which was conducted by the National Institute of Allergy and Infectious Diseases (NIAID). The EUA was issued to Eli Lilly and Company.
Sources: en.wikipedia.org
No. Cardarine is GW501516, a PPARδ agonist, while SARMs act on androgen receptors. The two classes are often grouped in informal discussions despite different mechanisms.
No. It has no approved medical indication in any country. Regulatory agencies have not cleared it for treatment or prevention of any condition.
Early clinical work stopped after rodent carcinogenicity findings. Those animal results raised concerns about long-term human risk, although direct human evidence is lacking. The human relevance of the tumors remains an open scientific question.
Anti-doping and clinical laboratories commonly use liquid chromatography-tandem mass spectrometry. The method can identify GW501516 and its metabolites in urine or blood. Detection depends on sample timing and the amount present.